We are live on ! Find out more
FCM

Farallon Capital Management Portfolio holdings

AUM $17.5B
1-Year Est. Return 50.95%
This Fund
S&P 500
This Quarter Est. Return
-0.05%
1 Year Est. Return
+50.95%
3 Year Est. Return
+148.38%
5 Year Est. Return
+206.05%
10 Year Est. Return
+1,475.31%
AUM
$17.5B
AUM Growth
-$4.53B
Cap. Flow
-$3.73B
Cap. Flow %
-21.26%
Top 10 Hldgs %
49.23%
Holding
203
New
48
Increased
29
Reduced
30
Closed
31

Top Buys

Rank Stock Value
1
AVGO icon
Broadcom
AVGO
+$292M
2
KKR icon
KKR & Co
KKR
+$280M
3
ROIV icon
Roivant Sciences
ROIV
+$248M
4
MA icon
Mastercard
MA
+$138M
5
TMO icon
Thermo Fisher Scientific
TMO
+$133M

Top Sells

Rank Stock Value
1
EXAS
Exact Sciences
EXAS
+$650M
2
CYBR
CyberArk
CYBR
+$470M
3
CRM icon
Salesforce
CRM
+$334M
4
NDAQ icon
Nasdaq
NDAQ
+$290M
5
RNAM
Avidity Biosciences
RNAM
+$233M

Sector Composition

Rank Sector Weight
1 Healthcare 50.56%
2 Financials 12.21%
3 Technology 11.18%
4 Consumer Discretionary 5.09%
5 Industrials 3.93%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SLS icon
151
SELLAS Life Sciences
SLS
$2.45B
$169K ﹤0.01%
+40,000
New +$179K
ADPT icon
152
Adaptive Biotechnologies
ADPT
$3.5B
$153K ﹤0.01%
11,000
– –
OCUL icon
153
Ocular Therapeutix
OCUL
$1.91B
$152K ﹤0.01%
18,000
– –
NEO icon
154
NeoGenomics
NEO
$1.85B
$141K ﹤0.01%
19,000
– –
ARDX icon
155
Ardelyx
ARDX
$1.26B
$138K ﹤0.01%
23,000
– –
OSCR icon
156
Oscar Health
OSCR
$8.92B
$126K ﹤0.01%
11,000
-253,000
-96% -$3.56M
NUVB icon
157
Nuvation Bio
NUVB
$2.18B
$124K ﹤0.01%
29,000
– –
IOVA icon
158
Iovance Biotherapeutics
IOVA
$2.24B
$91.3K ﹤0.01%
26,000
– –
SLDPW icon
159
Solid Power Inc Warrant
SLDPW
$13.7M
$88.4K ﹤0.01%
405,316
– –
ALT icon
160
Altimmune
ALT
$546M
$85K ﹤0.01%
27,600
– –
CCCC icon
161
C4 Therapeutics
CCCC
$396M
$73.6K ﹤0.01%
28,000
– –
TVRD
162
Tvardi Therapeutics
TVRD
$27.5M
$68.2K ﹤0.01%
21,438
-21,787
-50% -$85.4K
GERN icon
163
Geron
GERN
$924M
$64.1K ﹤0.01%
43,000
– –
BGLWW
164
Blue Gold Ltd Warrant
BGLWW
$920K
$60K ﹤0.01%
300,000
– –
RANI icon
165
Rani Therapeutics
RANI
$77.1M
$57.3K ﹤0.01%
78,000
– –
IRWD icon
166
Ironwood Pharmaceuticals
IRWD
$634M
$45.6K ﹤0.01%
13,000
– –
EVH icon
167
Evolent Health
EVH
$667M
$31.9K ﹤0.01%
14,000
– –
CGC
168
Canopy Growth
CGC
$394M
$28.5K ﹤0.01%
30,000
– –
NVNIW
169
Nvni Group Limited Warrants
NVNIW
$788K
$17.8K ﹤0.01%
375,000
– –
BYND icon
170
Beyond Meat
BYND
$306M
$13.3K ﹤0.01%
19,000
– –
ACLX
171
DELISTED
Arcellx
ACLX
– –
-4,000
Closed -$261K
ALNY icon
172
PUT
Alnylam Pharmaceuticals
ALNY
$36.4B
– –
-100,000
Closed -$39.8M
ASND icon
173
Ascendis Pharma A/S
ASND
$16.5B
– –
-1,400
Closed -$299K
CBRE icon
174
CBRE Group
CBRE
$40.6B
– –
-983,771
Closed -$158M
CDTX
175
DELISTED
Cidara Therapeutics
CDTX
– –
-382,800
Closed -$84.6M
5 6
7
8 9

Similar funds

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Farallon Capital Management's Q1 2026 Portfolio in Review

As of Q1 2026, Farallon Capital Management held 203 positions worth $17.5B, down 21% from $22.1B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Farallon Capital Management withdrew a net $3.73B in Q1 2026, closing 31 positions and reducing 30 holdings. Its most notable exit was Exact Sciences, an estimated $650M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 51% of assets, up from 43% a quarter earlier, followed by Financials and Technology.

Against the trend, Farallon Capital Management opened a new position in Dianthus Therapeutics worth $70.2M.

  • Farallon Capital Management's largest Q1 2026 buy was Dianthus Therapeutics: 836,000 shares worth $70.2M.
  • Farallon Capital Management added most to Broadcom in Q1 2026, an estimated $292M increase.
  • Farallon Capital Management's biggest Q1 2026 reduction was Wabtec, cutting an estimated $210M.
  • Farallon Capital Management fully exited Exact Sciences in Q1 2026, selling an estimated $650M.
  • Farallon Capital Management's ten largest holdings make up 49% of its $17.5B portfolio in Q1 2026.
  • Farallon Capital Management opened 48 new positions and closed 31 in Q1 2026.
  • Farallon Capital Management's portfolio value fell 21% quarter-over-quarter to $17.5B.

Based on Farallon Capital Management's 13F filing for Q1 2026, filed 15 May 2026.